Celcuity Announced At ESMO Saturday, Phase 3 VIKTORIA-1 Data In PIK3CA-Mutant Breast Cancer Showing 59% ORR, 19.4-Month DOR For Gedatolisib Triplet, 43%, 27.8 Months For Doublet Vs. 33%, 7.5 Months For Alpelisib + Fulvestrant

Loading news article.

Celcuity Announced At ESMO Saturday, Phase 3 VIKTORIA-1 Data In PIK3CA-Mutant Breast Cancer Showing 59% ORR, 19.4-Month DOR For Gedatolisib Triplet, 43%, 27.8 Months For Doublet Vs. 33%, 7.5 Months For Alpelisib + Fulvestrant | WAPE

Celcuity Announced At ESMO Saturday, Phase 3 VIKTORIA-1 Data In PIK3CA-Mutant Breast Cancer Showing 59% ORR, 19.4-Month DOR For Gedatolisib Triplet, 43%, 27.8 Months For Doublet Vs. 33%, 7.5 Months For Alpelisib + Fulvestrant

Article summary

Related companies

Comments —